For example, the STAT inhibitor Fludarabine has been approved for the treatment of B-cell chronic lymphocytic leukemia; the JAK inhibitor Upadacitinib has been approved for the treatment of moderately to severely active rheumatoid arthritis or active psoriatic arthritis; and the STAT inhibitor Stattic can exert an inhibitory effect on the auto-inflammatory response in myeloid, lymphatic and neuronal tissue compartments by inhibiting STAT3 (Alhazzani et al., 2021). The gene discussed is SOAT1; the disease is B-cell chronic lymphocytic leukemia.